Notably, the 200–216 AA sequence of P2X7R was selectively exposed in nf P2X7 but not in “wild-type” P2X7R in several cancer types, and antibodies targeting this sequence have been developed as therapeutics (Gilbert et al., 2019). Here, P2RX7 is linked to cancer.